Screening for Down Syndrome using first-trimester combined screening followed by second trimester ultrasound examination in an unselected population;Dépistage de la trisomie 21 par le test combiné du premier trimestre suivi par l'échographie du second trimestre en population générale

Gynecologie Obstetrique et Fertilite

Volumn 35, Issue 4, 2007, Pages 303-311

  Rozenberg, P ^a   Bussieres L ^b   Chevret, S ^b   Bernard, J P ^a   Malagrida, L ^a   Cuckle, H ^c   Chabry, C ^d   Durand Zaleski, I ^e   Bidat, L ^a   Lacroix, I ^f   Moulis, M ^g   Roger, M ^h   Jacquemot, M C ⁱ   Bault, J P ^j   Boukobza, P ⁱ   Boccara, P ^k   Vialat, F ^a   Giudicelli, Y ^a   Ville, Y ^a  

^a CENTRE HOSPITALIER INTERCOMMUNAL   (France)

^b SAINT LOUIS HOSPITAL   (France)

^c UNIVERSITY OF LEEDS   (United Kingdom)

^d Caisse Nationale d'Assurance Maladie des Travailleurs Salaries   (France)

^e HENRI MONDOR HOSPITAL   (France)

^f LABORATOIRE CERBA   (France)

^g Hopital de Mantes   (France)

^h LCL Paris Laboratory   (France)

ⁱ Centre hospitalier Henri Mignot   (France)

^j Samu 28 Hôpital de Dreux   (France)

^k Emergency Department   (France)

more..

Author keywords

Cost; Down syndrome; Fetal nuchal translucency; Free human chorionic gonadotropin; Pregnancy associated plasma protein A; Screening; Ultrasound

Indexed keywords

ALPHA FETOPROTEIN; CHORIONIC GONADOTROPIN BETA SUBUNIT; BIOLOGICAL MARKER;

ADULT; ARTICLE; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DOWN SYNDROME; FEMALE; FETUS ECHOGRAPHY; FIRST TRIMESTER PREGNANCY; HUMAN; MATERNAL SERUM; PREVALENCE; SCREENING TEST; SECOND TRIMESTER PREGNANCY; TRISOMY 21; BLOOD; CLINICAL TRIAL; COST; DIFFERENTIAL DIAGNOSIS; ECHOGRAPHY; ECONOMICS; MATERNAL AGE; METHODOLOGY; MULTICENTER STUDY; NUCHAL TRANSLUCENCY MEASUREMENT; PREGNANCY; PRENATAL DIAGNOSIS; RISK FACTOR;

ADULT; BIOLOGICAL MARKERS; COSTS AND COST ANALYSIS; DIAGNOSIS, DIFFERENTIAL; DOWN SYNDROME; FEMALE; HUMANS; MATERNAL AGE; NUCHAL TRANSLUCENCY MEASUREMENT; PREGNANCY; PREGNANCY TRIMESTER, FIRST; PREGNANCY TRIMESTER, SECOND; PRENATAL DIAGNOSIS; RISK FACTORS; ULTRASONOGRAPHY, PRENATAL;

EID: 34147204379     PISSN: 12979589     EISSN: 17696682     Source Type: Journal    
DOI: 10.1016/j.gyobfe.2007.02.004     Document Type: Article

References (46)

1. Wald N.J., Kennard A., Hackshaw A., and McGuire A. Antenatal screening for Down's syndrome. J. Med. Screen. 4 (1997) 181-246
2. Snijders R.J., Noble P., Sebire N., Souka A., and Nicolaides K.H. UK multicenter project on assessment of risk of trisomy 21 by maternal age and fetal nuchal-translucency thickness at 10-14 weeks of gestation. Lancet 351 (1998) 343-346
3. Haddow J.E., Palomaki G.E., Knight G.J., Williams J., Miller W.A., and Johnson A. Screening of maternal serum for fetal Down's syndrome in the first trimester. N. Engl. J. Med. 338 (1998) 955-961
4. Canick J.A., and Kellner L.H. First trimester serum screening for aneuploidy: serum biochemical markers. Semin. Perinatol. 23 (1999) 359-368
5. De Biasio P., Siccardi M., Volpe G., Famularo L., Santi F., and Canini S. First-trimester screening for Down syndrome using nuchal translucency measurement with free [beta]-hCG and PAPP-A between 10 and 13 weeks of pregnancy-the combined test. Prenat. Diagn. 19 (1999) 360-363
6. Krantz D.A., Hallahan T.W., Orlandi F., Buchanan P., Larsen J.W., and Macri J.N. First-trimester Down syndrome screening using dried blood biochemistry and nuchal translucency. Obstet. Gynecol. 96 (2000) 207-213
7. Niemimaa M., Suonpaa M., Perheentupa A., Seppala M., Heinonen S., Laitinen P., et al. Evaluation of first trimester maternal serum and ultrasound screening for Down's syndrome in Eastern and Northern Finland. Eur. J. Hum. Genet. 9 (2001) 404-408
8. Schuchter K., Hafner E., Stangl G., Metzenbauer M., Hofinger D., and Philipp K. The first trimester 'combined test' for the detection of Down syndrome pregnancies in 4939 unselected pregnancies. Prenat. Diagn. 22 (2002) 211-215
9. Crossley J.A., Aitken D.A., Cameron A.D., McBride E., and Connor J.M. Combined ultrasound and biochemical screening for Down's syndrome in the first trimester: a Scottish multicenter study. Br. J. Obstet. Gynaecol. 109 (2002) 667-676
10. Bindra R., Heath V., Liao A., Spencer K., and Nicolaides K.H. One-stop clinic for assessment of risk for trisomy 21 at 11-14 weeks: a prospective study of 15,030 pregnancies. Ultrasound Obstet. Gynecol. 20 (2002) 219-225
11. Wapner R., Thom E., Simpson J.L., Pergament E., Silver R., Filkins K., et al., First Trimester Maternal Serum Biochemistry and Fetal Nuchal Translucency Screening (BUN) Study Group. First-trimester screening for trisomies 21 and 18. N. Engl. J. Med. 349 (2003) 1405-1413
12. Wald N.J., Rodeck C., Hackshaw A.K., Walters J., Chitty L., and Mackinson A.M. First and second trimester antenatal screening for Down's syndrome: the results of the Serum, Urine and Ultrasound Screening Study (SURUSS). J. Med. Screen. 10 (2003) 56-104
13. Malone F.D., Canick J.A., Ball R.H., Nyberg D.A., Comstock C.H., Bukowski R., et al. First- and Second-Trimester Evaluation of Risk (FASTER) Research Consortium. First-trimester or second-trimester screening, or both, for Down's syndrome. N. Engl. J. Med. 353 (2005) 2001-2011
14. Goldberg J.D. Down's syndrome screening: confusion or consensus?. BJOG 111 (2004) 517-518
15. Nyberg D.A., Luthy D.A., Resta R.G., Nyberg B.C., and Williams M.A. Age-adjusted ultrasound risk assessment for fetal Down's syndrome during the second trimester: description of the method and analysis of 142 cases. Ultrasound Obstet. Gynecol. 12 (1998) 8-14
16. Benacerraf B.R., Barss V.A., and Laboda L.A. A sonographic sign for the detection in the second trimester of the fetus with Down's syndrome. Am. J. Obstet. Gynecol. 151 (1985) 1078-1079
17. Nicolaides K.H., Sebire N.J., and Snijders R. The 11-14 week scan (1999), The Parthenon Publishing Group, London
18. Economides D.L., Whitlow B.J., and Braithwaite J.M. Ultrasonography in the detection of fetal anomalies in early pregnancy. Br. J. Obstet. Gynaecol. 106 (1999) 516-523
19. Whitlow B.J., Chatzipapas I.K., Lazanakis M.L., Kadir R.A., and Economides D.L. The value of sonography in early pregnancy for the detection of fetal abnormalities in an unselected population. Br. J. Obstet. Gynaecol. 106 (1999) 929-936
20. DeVore G.R. Trisomy 21: 91% detection rate using second-trimester ultrasound markers. Ultrasound Obstet. Gynecol. 16 (2000) 133-141
21. Herman A., Maymon R., Dreazen E., Caspi E., Bukovsky I., and Weinraub Z. Nuchal translucency audit: a novel image-scoring method. Ultrasound Obstet. Gynecol. 12 (1998) 398-403
22. Kadir R.A., and Economides D.L. The effect of nuchal translucency measurement on second-trimester biochemical screening for Down's syndrome. Ultrasound Obstet. Gynecol. 9 (1997) 244-247
23. Hackshaw A.K., and Wald N.J. Inaccurate estimation of risk in second trimester serum screening for Down syndrome among women who have already had first trimester screening. Prenat. Diagn. 21 (2001) 741-746
24. Nicolaides K.H., Snijders R.J., and Cuckle H.S. Correct estimation of parameters for ultrasound nuchal translucency screening. Prenat. Diagn. 18 (1998) 519-523
25. Begg C.B., and Greenes R.A. Assessment of diagnostic tests when disease verification is subject to selection bias. Biometrics 39 (1983) 207-215
26. Cecil M.P., Kosinski A.S., Jones M.T., Taylor A., Alazraki N.P., Pettigrew R.I., et al. The importance of work-up (verification) bias correction in assessing the accuracy of SPECT thallium-201 testing for the diagnosis of coronary artery disease. J. Clin. Epidemiol. 49 (1996) 735-742
27. Kosinski A.S., and Barnhart H.X. A global sensitivity analysis of performance of a medical diagnostic test when verification bias is present. Stat. Med. 22 (2003) 2711-2721
28. Snijders R.J., Sundberg K., Holzgreve W., Henry G., and Nicolaides K.H. Maternal age - and gestation - specific risk for trisomy 21. Ultrasound Obstet. Gynecol. 13 (1999) 167-170
29. Benacerraf B.R., Nadel A., and Bromley B. Identification of second-trimester fetuses with autosomal trisomy by use of a sonographic scoring index. Radiology 193 (1994) 135-140
30. Bromley B., Lieberman E., and Benacerraf B.R. The incorporation of maternal age into the sonographic scoring index for the detection at 14-20 weeks of fetuses with Down's syndrome. Ultrasound Obstet. Gynecol. 10 (1997) 321-324
31. Cuckle H., Benn P., and Wright D. Down syndrome screening in the first and/or second trimester: model predicted performance using meta-analysis parameters. Semin. Perinatol. 29 (2005) 252-257
32. Benn P.A., Kaminsky L.M., Ying J., Borgida A.F., and Egan J.F. Combined second-trimester biochemical and ultrasound screening for Down syndrome. Obstet. Gynecol. 100 (2002) 1168-1176
33. Leporrier N., Herrou M., Morello R., and Leymarie P. Fetuses with Down's Syndrome detected by prenatal screening are more likely to abort spontaneously than fetuses with Down's Syndrome not detected by prenatal screening. BJOG 110 (2003) 18-21
34. Platt L.D., Greene N., Johnson A., Zachary J., Thom E., Krantz D., et al., First Trimester Maternal Serum Biochemistry and Fetal Nuchal Translucency Screening (BUN) Study Group. Sequential pathways of testing after first-trimester screening for trisomy 21. Obstet. Gynecol. 104 (2004) 661-666
35. Benacerraf B.R. Should sonographic screening for fetal Down syndrome be applied to low risk women?. Ultrasound Obstet. Gynecol. 15 (2000) 451-455
36. Nicolaides K., Shawwa L., Brizot M., and Snijders R. Ultrasonographically detectable markers of fetal chromosomal defects. Ultrasound Obstet Gynecol. 1 3 (1993) 56-69
37. Vintzileos A.M., and Egan J.F. Adjusting the risk for trisomy 21 on the basis of second-trimester ultrasonography. Am. J. Obstet. Gynecol. 172 (1995) 837-844
38. Vintzileos A.M., Campbell W.A., Rodis J.F., Guzman E.R., Smulian J.C., and Knuppel R.A. The use of second-trimester genetic sonogram in guiding clinical management of patients at increased risk for fetal trisomy 21. Obstet. Gynecol. 87 (1996) 948-952
39. Winter T.C., Uhrich S.B., Souter V.L., and Nyberg D.A. The "genetic sonogram": comparison of the index scoring system with the age-adjusted US risk assessment. Radiology 215 (2000) 775-782
40. Egan J.F., Malakh L., Turner G.W., Markenson G., Wax J.R., and Benn P.A. Role of ultrasound for Down syndrome screening in advanced maternal age. Am. J. Obstet. Gynecol. 185 (2001) 1028-1031
41. Simpson J.L. Choosing the best prenatal screening protocol. N. Engl. J. Med. 353 (2005) 2068-2070
42. Hagard S., and Carter A.C. Preventing the birth of infants with Down's syndrome: a cost-benefit analysis. BMJ 1 (1976) 753-756
43. Golstein H., and Philip J. A cost-benefit analysis of prenatal diagnosis by amniocentesis in Denmark. Clin. Genet. 37 (1990) 241-263
44. Heckerling P.S., and Verp M.S. A cost-effectiveness analysis of amniocentesis and chorionic villus sampling for prenatal genetic testing. Med. Care 32 (1994) 863-880
45. Gilbert R., Augood C., Gupta R., Ades A., Logan S., Sculpher M., et al. Screening for Down's syndrome: effects, safety, and cost effectiveness of first and second trimester strategies. BMJ 323 (2001) 423
46. Malone F.D., D'Alton M.E., and Society for Maternal-Fetal Medicine. First-trimester sonographic screening for Down syndrome. Obstet. Gynecol. 102 (2003) 1066-1079